HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MusclePharm Sheds 75% Of Portfolio, Flexes After Spending Stretched It Thin

This article was originally published in The Rose Sheet

Executive Summary

MusclePharm whittled its product line from 450 to 120 SKUs  and is shifting its distribution focus in the US from specialty retail to Amazon and Costco. The firm also cut operating costs, spending $10m less in 2017 than in 2016.

You may also be interested in...



US Wellness Market Q2 Results: USANA and Mannatech Climb, MusclePharm Slips On Costs

USANA expanding Active Nutrition line outside North America and extending it with bars, other products to attract additional customers as it transitions to a more holistic focus; MusclePharm ready for energy lines to drive sales; and Mannatech sales up with associates, customers up.

MusclePharm Lines Up Down Under, US Distributors To Dip Toe In Energy Beverages, Appoints President

It's working with former Rockstar energy drink brand executive to move into the energy drink space after previous false starts. Also names former Yum! Brands executive Sabina Rizvi president and CFO.

Health, Beauty And Wellness Business News: PepsiCo Incubates In Wellness, Cost-Cutting Spurs Profit At FitLife

Harvest Health in cannabidiol wellness with CBx Enterprises; MusclePharm revenues climb 12%; Celsius beverage sales up on retail expansion; CarnoSyn beta-alanine sales drive Natural Alternatives' growth; FitLife shows profit as cost-cutting continues; and PepsiCo incubates wellness start-ups.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS121661

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel